CSS
NVCR icon

Cubist Systematic Strategies’s NovoCure NVCR Stock Holding History

Cubist Systematic Strategies’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.08M Sell
393,333
-251,850
-39% -$3.36M 0.02% 955
2025
Q2 		$11.5M Buy
645,183
+393,565
+156% +$6.86M 0.05% 532
2025
Q1 		$4.48M Sell
251,618
-83,600
-25% -$1.9M 0.03% 945
2024
Q4 		$9.99M Buy
335,218
+231,466
+223% +$4.9M 0.06% 468
2024
Q3 		$1.62M Sell
103,752
-250,281
-71% -$4.54M 0.01% 1539
2024
Q2 		$6.06M Sell
354,033
-559,768
-61% -$9.84M 0.04% 660
2024
Q1 		$14.3M Buy
913,801
+296,433
+48% +$4.36M 0.08% 321
2023
Q4 		$9.22M Sell
617,368
-182,987
-23% -$2.45M 0.06% 496
2023
Q3 		$12.9M Buy
800,355
+785,498
+5,287% +$22.6M 0.1% 270
2023
Q2 		$617K Sell
14,857
-74,398
-83% -$4.62M ﹤0.01% 2262
2023
Q1 		$5.37M Buy
+89,255
New +$7.13M 0.03% 867
2022
Q4 		– Sell
-71,463
Closed -$5.43M – 4488
2022
Q3 		$5.43M Buy
71,463
+11,218
+19% +$875K 0.03% 1006
2022
Q2 		$4.19M Sell
60,245
-17,074
-22% -$1.29M 0.03% 1152
2022
Q1 		$6.41M Sell
77,319
-50,969
-40% -$3.75M 0.05% 547
2021
Q4 		$9.63M Buy
128,288
+91,960
+253% +$9.23M 0.09% 263
2021
Q3 		$4.22M Buy
36,328
+21,354
+143% +$3.23M 0.05% 544
2021
Q2 		$3.32M Sell
14,974
-65,846
-81% -$12.8M 0.04% 770
2021
Q1 		$10.7M Buy
80,820
+23,631
+41% +$3.74M 0.14% 143
2020
Q4 		$9.9M Buy
57,189
+27,717
+94% +$3.79M 0.14% 164
2020
Q3 		$3.28M Sell
29,472
-193,966
-87% -$15.5M 0.05% 612
2020
Q2 		$13.3M Buy
223,438
+199,621
+838% +$13.1M 0.23% 70
2020
Q1 		$1.6M Sell
23,817
-14,892
-38% -$1.18M 0.04% 570
2019
Q4 		$3.26M Buy
38,709
+13,844
+56% +$1.12M 0.06% 480
2019
Q3 		$1.86M Sell
24,865
-18,562
-43% -$1.48M 0.04% 658
2019
Q2 		$2.75M Sell
43,427
-19,611
-31% -$994K 0.05% 538
2019
Q1 		$3.04M Buy
+63,038
New +$3.03M 0.1% 284
2018
Q4 		– Sell
-4,379
Closed -$229K – 2217
2018
Q3 		$229K Buy
+4,379
New +$174K 0.01% 1338
2016
Q1 		– Sell
-13,115
Closed -$293K – 1764
2015
Q4 		$293K Buy
+13,115
New +$313K 0.02% 1129

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's NVCR Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its NovoCure (NVCR) stake by 39% in Q3 2025, selling an estimated $3.36M and leaving 393,333 shares worth $5.08M. The position accounts for 0.02% of the portfolio, ranked #955.

Cubist Systematic Strategies first reported a position in NVCR in Q4 2015 and has held it in 28 quarters since. The position peaked at $14.3M in Q1 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Cubist Systematic Strategies held 393,333 shares of NovoCure worth $5.08M as of Q3 2025.
  • Cubist Systematic Strategies sold 251,850 NovoCure shares in Q3 2025, an estimated $3.36M.
  • NovoCure made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #955 holding.
  • Cubist Systematic Strategies first reported a position in NovoCure in Q4 2015 and has held it in 28 quarters since.
  • Cubist Systematic Strategies's NovoCure position peaked at $14.3M in Q1 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.